Abstract | The release of membrane-bound vesicles from cells is being increasingly recognized as a mechanism of intercellular communication. Extracellular vesicles (EVs) or exosomes are produced by virus-infected cells and are thought to be involved in intercellular communication between infected and uninfected cells. Viruses, in particular oncogenic viruses and viruses that establish chronic infections, have been shown to modulate the production and content of EVs. Viral microRNAs, proteins and even entire virions can be incorporated into EVs, which can affect the immune recognition of viruses or modulate neighbouring cells. In this Review, we discuss the roles that EVs have during viral infection to either promote or restrict viral replication in target cells. We will also discuss our current understanding of the molecular mechanisms that underlie these roles, the potential consequences for the infected host and possible future diagnostic applications.
Extracellular vesicles (EVs) are secreted from healthy, malignant and virus-infected cells. EVs are either released directly from the plasma membrane or during fusion between multivesicular bodies (MVBs) and the plasma membrane 1, 2 . EVs that are released from MVBs are termed exosomes. Similar to EVs, viruses are released through several pathways, including the plasma membrane and through the MVB route (reviewed in REF. 3 ). For example, some retroviruses, such as HIV-1, assemble at the inner leaflet of the plasma membrane, whereas other retroviruses, such as Mason-Pfizer monkey virus (MPMV), first assemble in the cytoplasm before trafficking to the cell surface (reviewed in REF. 4 ). Some viruses are non-enveloped and do not require an envelope for infectivity, but, nevertheless, they can be incorporated into EVs for their release. For example, hepatitis A virus (HAV) was recently shown to be secreted within EVs that can potentially be transported to uninfected cells in an individual who is infected 5, 6 . Other enteroviruses can package up to ~20 particles in a single membrane vesicle and bud without killing the host cell 7 . Autophagy, which is thought to provide nutrients to the cell through the digestion of intracellular organelles, can also be used for virus egress. For example, enteroviruses exit infected cells in autophagic membranes and these membranes form part of the envelope for herpesviruses, paramyxoviruses and orthomyxo viruses 8 . Lipidated microtubule-associated protein 1 light chain 3 (LC3), which is a marker of autophagosomes, has been detected in EVs that contain coxsackie virus. In addition, the exosome marker flotillin-1 was found in these vesicles, which suggests that picorna viruses use autophagy-related EV release as one pathway for virion exocytosis 9 . EVs are thought to have an important role in virus infection and several interactions between viral and cellu lar components that are required for the biogenesis of EVs have been reported. Therefore, a critical comparison between virus particles and EVs may lead to an improved understanding of both virus life cycles and the functions of EVs.
Owing to their small size and similar biochemical composition, viruses and EVs have similar biophysical properties. The term exosome is used if EVs are ≤100 nm in diameter and originate from MVBs, the term microvesicle is used if the diameter is 100-1,000 nm and the term apoptotic body is used if the diameter is >1,000 nm. Similarly, viruses range in diameter from 30 nm for poliovirus, 120-140 nm for herpesviruses and 200-300 nm for poxviruses (reviewed in REF. 10 ). This similarity in biophysical properties increases the difficulty in obtaining pure populations of EVs that are not contaminated with viruses and vice versa. This makes it challenging to determine the precise composition of EVs and virions (BOX 1) . The identification and characterization of virion-associated proteins have been the subject of intense study over many years 11 , whereas the identification of proteins that are associated with EVs has been more recent. Studies have identified key components of EVs that can be used as markers to identify and assess their purity (TABLE 1) ; however, it is important to recognize that not all EVs have these markers 12 . In the context 1 
Biomarker
A protein, mRNA or other small molecule that can be measured and is associated with disease outcome, either independent of treatment (prognostic) or in relation to treatment (predictive).
Crowding agents
Chemicals, such as polyethylene glycol or acetone that change the availability of free solvent for proteins and other macromolecular structures, which results in aggregation.
of virus infection, viral RNAs and proteins have been found in EVs [13] [14] [15] [16] , which could be the result of selective incorporation of specific RNAs and these proteins or, alternatively, reflect the total intracellular constituents. Further work is required to determine the precise composition of EVs. The development of mass spectrometers that have enhanced specificities and sensitivities compared with existing instruments will undoubtedly improve our understanding of the composition of EVs. Further work is also required to optimize the purification of EVs; therefore, careful consideration is required when attributing functional phenotypes to EVs in the context of virus infection.
Research into understanding the roles that EVs have in viral infections is driven, to a large extent, by interests in biomarker development. For example, the microRNA (miRNA) miR-122, which is incorporated into EVs during acute liver injury, could be used as a biomarker to determine the extent of damage to the liver [17] [18] [19] . miR-122 is the most abundant miRNA in liver cells and perhaps, owing to this abundance, it is incorporated into EVs. The correlation between the levels of miR-122 and alanine aminotransferase, an enzyme that is also released when the liver is damaged, has been established in the clinic. Therefore, miR-122 could be used as an alternative, more specific biomarker to alanine aminotransferase in the clinic. Notably, miR-122 is also required for the replication of hepatitis C virus (HCV) and is therefore an attractive drug target for the development of new therapies against HCV [20] [21] [22] . The success of such therapies could be determined by minimally invasive profiling of EVs and plasma miR-122 levels, as miR-122 would provide information about liver cell status in addition to viral load. The use of highly multiplexed assays that are able to detect multiple mi RNAs and viruses, next-generation sequencing and mass spectrometry will help drive the research of EVs for diagnostic applications.
Studying EVs in the context of virus infection has been crucial for demonstrating the potential contribution of these vesicles to viral pathogenesis 23 , as EVs from virus-infected cells often transfer viral components to uninfected cells; for example, latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) and viral mi RNAs 16, 24 . This intercellular transfer of viral cargo occurs in the absence of cell-to-cell fusion, cellular synapses or membrane nanotubes [25] [26] [27] , and represents the existence of a host transfer mechanism that occurs in the absence of virus spread. Roles for intercellular transport by EVs have been described; for example, in mediating cross-presentation for T cells [28] [29] [30] and synaptic transmissions 31 . Many of the vesicles used during these processes have features of biogenesis and fusion mechanisms that are similar to EVs and viruses. Of note, in the context of cross-priming, the vesicles tend to stay in the immediate microenvironment, such as the lymph nodes, and are not found circulating systemically in body fluids.
In this Review, we will focus on the molecular and biological properties of EVs that are released from virus-infected cells. In addition, we consider how the EVs that are modified by viruses may either facilitate viral infection or promote resistance to immune recognition by antibodies or the inhibition of innate immunity. In particular, we will focus on human viral infections with HIV-1, HAV and HCV, and the two herpesviruses EBV and Kaposi sarcoma-associated herpes virus (KSHV). It is in the context of these chronic, persistent and latent infections that the effects of viruses on the content and function of EVs have been studied the most.
Biological roles for EVs in viral infections
Oncogenic viruses and viruses that are able to establish long-term persistent infections have been shown to alter the content of EVs, which has been hypothesized to facilitate infection and contribute to persistence and pathogenesis. Persistent and chronic infections are characterized by low levels of virus replication and low levels of circulating virus particles (~10 1 -10 4 particles per ml) 3 . By contrast, during latent infections viruses cannot be detected in the circulation. Latency has a defining role
Box 1 | Distinguishing EVs from virions
The purity of any preparation of extracellular vesicles (EVs) is determined by measuring light-scatter and Brownian motion, and by electron microscopy (FIG. 2) . More recently, flow cytometry-based methods have been introduced, but the small size of EVs makes them difficult to detect using conventional instruments. EVs can be isolated by size-exclusion chromatography, differential ultracentrifugation, density flotation, crowding agents, flow cytometry or affinity purification (TABLE 1) ; each method has specific advantages 158 . Size-exclusion chromatography is the best method for preserving the structure of EVs [159] [160] [161] , although it does not separate virions from EVs 11, 151, 162 . The use of crowding agents, such as polyethylene glycol (PEG) 3,000, followed by precipitation is the fastest way to isolate and concentrate EVs for subsequent applications; however, this approach also enriches soluble proteins and contaminants that are not a part of EVs. When profiling microRNAs (mi RNAs) in EVs, it is important to consider that Argonaute (Ago)-associated mi RNAs are present in serum 163 . These Ago-miRNA complexes also co-purify with EVs when only crowding agents are used; however, this problem can be circumvented through the use of affinity-based purification methods. Affinity purification using magnetic beads enables the high-throughput purification of EVs on robot platforms and it is able to separate EVs from viruses 13 . For example, EVs from B cell lymphomas are enriched for B cell surface antigens, including CD81 and CD63, which can be used to affinity purify EVs using antibodies that bind to these proteins 164 . However, this approach will exclude populations of EVs that do not have the particular surface marker used for affinity purification, but that may nevertheless contribute to the biological functions of EVs 12 . 
Method

Cross-priming
The transfer of antigens from one cell to another cell, often to a professional antigenpresenting cell, that does not make the antigen; the phrase was originally coined to explain counterintuitive aspects of T cell responses.
Latent infections
The long-term presence of viral genomes (DNA or RNA) in a cell without any evidence of virion production.
Capsid
Proteins that encapsulate viral genomes. Capsids are rigid, highly structured and are similar to crystals with a defined symmetry. The size, shape and symmetry of the capsid can be determined by electron microscopy and is sometimes used to classify viruses into taxa.
Endosomal sorting complex required for transport machinery in infections with herpesviruses and lentiviruses. In the case of latent herpesvirus infections, viral mi RNAs can be detected within EVs at times when conventional viral load assays are negative 13, 16, 24 . In the case of HIV-1, the viral protein Nef has been found in EVs that circulate in infected individuals [32] [33] [34] . 
The biogenesis of EVs
EVs are small membrane-bound carriers of intracellular cargo that are derived from MVBs or the plasma membrane (FIG. 1) . Unlike virus particles, the membranes of EVs do not enclose a structured core, such as a capsid. Specific properties of EVs define and distinguish them from other types of microvesicle 10 . The assembly of EVs is an active, energy-dependent and regulated process 39, 40 . Assembly has been shown to specifically require sphingo myelinase 41 and components of the endosomal sorting complex required for transport machinery (ESCRT machinery). The content of EVs is determined by the protein and RNA composition of the cells from which they were derived. The composition of EVs frequently reflects the relative abundance of contents in the EV-producing cell. Thus, EVs that are derived from virus-infected cells contain highly expressed viral mi RNAs 13, 16, 24 . In addition, several recent studies have provided evidence for differential loading, whereby the relative abundance of mi RNAs in the EV is distinct from that of the producing cell 16, 24, [42] [43] [44] [45] . The budding of EVs into MVBs requires the ESCRT proteins tumour susceptibility gene 101 protein (TSG101) and ALG2-interacting protein X (ALIX; also known as PDCD6IP), which are known markers of EVs 2 . TSG101 and ALIX are also required for the ESCRT-dependent budding of enveloped viruses from the plasma membrane, such as herpes simplex virus 1 (HSV-1) 46 ; therefore, it is difficult to determine using only these proteins as markers whether the EVs originated from MVBs or the plasma membrane. Other membrane proteins that localize to lipid rafts in the plasma membrane, including tetraspanins such as CD63 and CD81, are also enriched in EVs. Lipid raft localization involves palmitoylation 47 , which has been shown to be required for the incorporation of the LMP1 protein of EBV. LMP1 is enriched in lipid rafts and in EVs 48 . Depending on the experimental approach and cell line, other proteins, such as sortillin (SORT1), syntenin 1 (SDCBP) or syndecan 1 (SDC1), have also been found to have a role in the biogenesis of EVs [49] [50] [51] . The RAB family of small GTPases regulates several steps in the trafficking of vesicles to distinct endocytic compartments and they also function in the docking of MVBs to the plasma membrane (FIG. 1) . For example, the RAS-related proteins RAB11A and RAB35 function during the recycling and sorting endosomes, whereas RAB27A and RAB27B are essential for the secretion of EVs 52 . It is likely that some viruses modulate this process to facilitate viral entry, trafficking and egress. RAB6 and RAB7 also affect the flux between lysosomes and autophagosomes, and could contribute to determining the content of EVs [53] [54] [55] . Several viruses affect the expression of ESCRT and RAB GTPases to promote viral entry and egress, and are therefore likely to modulate the content of EVs 56 . In addition, it is known that members of the RAB family of GTPases interact with members of the RAL family of GTPases and function during intracellular 
RGD motif
The tripeptide Arg-Gly-Asp (RGD) is recognized by many integrins, either as part of a short peptide (blocking peptide) or as repeat region in extracellular matrix proteins.
Angiogenesis
The formation of new vessels that carry either blood or lymph, which involves the migration, growth and differentiation of endothelial cells.
Hyperimmune serum
Serum obtained from one, or many, infected convalescent animals that contains high levels of blocking antibodies to a target virus.
trafficking. In Caenorhabditis elegans, it has been shown that RAL-1 (the homologue of human RALA and RALB) regulates both the biogenesis of MVBs and the secretion of EVs 57 . Activated RAL-1 associates with syntaxin 5 (SYX-5), which is a soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex protein, at the plasma membrane and is required for the secretion of EVs. Interestingly, SYX5 is also required for the release of human cytomegalovirus (HCMV) and SYX4, another SNARE complex protein that has been found to regulate the release of HCV 58, 59 . Additional SNARE complex proteins have also been shown to interact with herpesvirus glycoproteins to promote release 60 . These examples demonstrate that viruses co-opt the cellu lar vesicular transport system during egress and are therefore likely to modulate the content and secretion of EVs through similar interactions.
Uptake of EVs
Viruses use cell surface receptors to initiate fusion with the plasma membrane and are known to use specific receptors to target specific cell types. This receptor speci ficity determines their cellular tropism and is a distinguishing feature compared with EVs, which have the ability to enter a wider range of cell types than viruses. Using fluorescent dyes that were incorporated into EVs, it was shown that the membranes of EVs can fuse with cell membranes 16, 24, 61, 62 . Most cell types that have been tested can fuse with EVs and therefore EVs can be used to deliver cargo to various cell types. This process is analogous to cationic lipid-mediated transfection approaches. In some cases, EVs use specific receptors for entry 12, 63 and therefore the fusion of EVs with cellular membranes can be tissue specific. For example, EVs produced by cells that are infected with EBV that express the viral glycoprotein gp350, or EVs that are engineered to express gp350, specifically target B cells that express the viral entry receptor CD21 and can block the infection of naive B cells by EBV 61, 64 . Heparin is involved in the initiation of host cell entry for many viruses, including retroviruses and herpesviruses 65 . It is a glycosaminoglycan that can bind to almost all viral envelopes. Thus, exogenous heparin or heparin beads can inhibit virion attachment through competitive binding. Cell surface-bound heparin is thought to concentrate virions before specific receptor and co-receptor engagement. Heparin is also thought to have a role in the entry of EVs 66 , although the fusion of EVs with the plasma membrane can occur at concentrations of heparin that block the entry of HSV-1. This provides an experimental tool to separate virion effects from EV phenotypes, as virus entry, even the entry of non-infectious or defective HSV-1 particles, can be blocked by heparin, which affirms the notion that EVs use different mechanisms for cell entry than most viruses.
Annexin A5 (and potentially other annexin family members) mediates the fusion of EVs to the plasma membrane through binding to phosphatidylserine 67 . Importantly, annexin A5 does not antagonize virus entry and thus can be used to distinguish EV-mediated phenotypes from virus particle or soluble moleculemediated phenotypes. Although the biogenesis of virions and EVs is similar, EVs and virions probably use different mechanisms to enter cells.
Integrins and integrin-binding matrix proteins, many of which contain a signature arginine, glycine and aspartic acid motif (RGD motif), have important roles in virus entry and their potential roles in the entry of EVs is also beginning to be understood 68, 69 . They are thought to act as attachment factors or co-receptors that synergize with the primary receptor for virus entry. Both EBV and KSHV use integrins as co-receptors for virus entry 70 . RGD peptides and integrin-specific antibodies can interfere with the attachment of virions and EVs to cells 68, 70 . They also affect signalling through the integrin homodimer and heterodimer, thus having pleiotropic effects on cell physiology. For example, the integrin-specific antibody etaracizumab is in clinical trials as anti-angiogenesis agent in non-virus associated cancers, because blocking integrin signalling can induce cell death.
Viruses have a strict requirement for cell-type specific receptors and co-receptors. These receptors engage specific envelope glycoproteins and trigger large molecular rearrangements to expose the components of the viral fusion complex. Hence, hyperimmune serum that is raised against virion components has clinical use in blocking infection; for example, in treating patients that have been exposed to Ebola virus 71 . By contrast, the entry of EVs is more promiscuous than viruses, and clathrindependent, caveolae-dependent, macropinocytosis 56, 62 , phagocytosis and lipid raft-mediated uptake 72 have all been shown to contribute to the entry of EVs (reviewed in REF. 63 ).
EVs in virus infection
Much of our knowledge about the physiological functions of systemically circulating EVs is derived from studies that have analysed their contribution to cancer metastasis [73] [74] [75] [76] 
. It was found that EVs released from tumour cells can modulate cells in the surrounding microenvironment and drive distant metastasis by modulating stromal cell growth, cell migration, growth factor secretion and vascular permeability. A supportive microenvironment (for example, by providing growth factors and extracellular matrix attachment opportunities and increased endothelial cell permeability), is also essential for systemic virus spread. In the following sections we will review how EVs contribute to viral infection.
HCV. HCV is a member of the Flaviviridae family. It is distinct from the arbovirus members of the Flaviviridae, as it is transmitted through blood-to-blood contact or through sexual intercourse rather than by an insect vector. HCV virions are enveloped and smaller than EVs (~50 nm in diameter compared with ~100 nm for EVs) 77 . EVs isolated from human hepatoma cell lines infected with HCV were shown to contain virions 78, 79 . Some of the subgenomic HCV RNA co-localizes with CD81 and CD63 (markers of EVs). The E2 protein of HCV was also found to colocalize with CD81 in EVs, and EVs were
Cytopathic effect
Changes in host cells that are caused by virus infection.
found to transport viral RNA to uninfec ted cells [79] [80] [81] . CD81 is the dominant co-receptor for HCV [82] [83] [84] ; therefore, it is likely that HCV virions are incorporated into EVs through their interaction with CD81. HCV RNA that is transmitted by EVs induces an innate interferon-α (IFNα) response in neighbouring dendritic cells (DCs). This is in contrast to natural HCV infection, which also delivers viral RNA to cells but downregulates Toll-like receptor (TLR) and RIG-I-like receptor (RLR) signalling through the action of the viral NS3/4 protease. Therefore, by specifically transporting viral RNA but not viral proteins, which antagonize innate immunity, EVs may provide a protective function for uninfected cells in the immediate microenvironment during infection.
Systemically circulating EVs that contain HCV virions may have a pro-viral role, as HCV was shown to spread in the presence of neutralizing antibodies 78, 85 . This spread may be facilitated by the masking of viral proteins in the EVs (FIG. 2a) . Such a strategy of host evasion, in which persistent viruses, such as HCV and more prominently HAV (see below), escape the evolutionary selection pressure of neutralizing antibodies by being incorporated in EVs, may be widespread. The carriage of HCV virions in EVs also suggests that HCV could enter additional cell types, in addition to hepatocytes, through EV-mediated fusion, in which case infection would not be dependent on the expression of a specific viral receptor.
HAV. HAV, which is a non-enveloped picornavirus, is the cause of acute enterically transmitted hepatitis and replicates efficiently in the liver. HAV rapidly replicates in susceptible cells and virus particles are subsequently released; however, no cytopathic effect has been observed. RNA-containing proteinaceous particles (with a density of 1.22-1.28 g ml -1 ) represent the major form of HAV in faeces 6 . HAV can be neutralized by antibodies that are elicited by current HAV vaccines. It has been shown that HAV can be released from cells in host-derived membranes at a density of 1.06-1.10 g ml
These HAV-containing EVs are infectious and circulate in the blood of infected individuals, whereas nonenveloped viruses have only been found in faeces 6 (FIG. 2b) . Two other picorna viruses, coxsackie B virus and enterovirus 71 (EV71), have also been found in EVs 7, 86, 87 . Two hypotheses have been formulated to explain the importance of EV-encapsulated picornaviruses as a biological mechanism rather than a side product of cellular inefficiency 6 . First, the envelopment of HAV by host membranes may expand the tropism of the virus, as EV surface proteins now engage the target cells rather than the viral surface proteins. This may provide an additional route for the spread of HAV within the liver and systemically to distant organs, such as the spleen, and lymph nodes, which function to filter and survey systemic fluids 3 . Second, the acquisition of a host membrane by HAV demonstrates that some non-enveloped viruses can acquire an envelope that is devoid of viral transmembrane proteins and thus provides evidence for an alternative egress pathway. This suggests that egress mediated by EVs would be distinct from the normal egress route. The acquisition of a host-derived membrane could also affect the recognition of HAV capsid proteins by antibodies and may enable persistence and spread in the presence of neutralizing antibodies. (≤5 × 10 3 virus particles per ml in plasma), HIV directly and indirectly modulates the immune system, leading to chronic pathology. Many of these indirect effects on the immune system are also observed in patients who are on antiretroviral therapy. Various hypotheses for this phenomenon have been proposed, including a role for EVs. In addition, soluble viral proteins, such as Tat, as well as secondary events to immunocompromise, such as extended lipopolysaccharide (LPS) translocation, may contribute to this phenotype 88, 89 (reviewed in REF. 36 ). The assembly of HIV-1 and the biogenesis of EVs have many similarities [90] [91] [92] . These similarities impair the biochemical and physical separation of EVs and virions, which include mature, immature and even defective particles. The molecular pathogenesis of HIV-1 suggests potential EV-mediated effects on neighbouring cells (FIG. 2c) , as the virus kills more abortively infected or uninfected T cells than infected cells [93] [94] [95] [96] . Cells infected with HIV may also release EVs that have trapped HIVvirions [94] [95] [96] [97] . More importantly, HIV encodes several accessory proteins, such as virion infectivity factor (Vif) 98 , that interfere with the cellular antiviral response. These pro-viral proteins may be carried by EVs to prime neighbouring cells to promote infection in what is known as the 'Trojan horse' hypothesis 23, 36 . Conversely,
HIV-1. HIV-1 is a human retrovirus that contains an
Box 2 | EVs in cancer
Approximately 20-30% of all cancers are associated with viral infections, and many features of cancer are also features of viral infection, such as dissemination (metastasis in cancer), uncontrolled DNA replication and metabolic perturbation (for example, glycolysis and nucleotide biogenesis). Therefore, insights that are gained from the study of the physiological phenotypes of extracellular vesicles (EVs) in the context of cancer and metastasis could also be relevant to understanding the role of EVs in viral persistence 165 . EVs have been extensively studied in cancer research, as they are released in high levels from tumour cells [73] [74] [75] [76] . The contents of EVs that are released from tumour cells mirror the contents of the producing cells. Therefore, these EVs are useful biomarkers, and the identification and characterization of EVs in body fluids from 'liquid biopsies' provide a non-invasive diagnostic and prognostic indicator for the development and progression of cancer 13, 131 . The identification of proteins such as p53, epidermal growth factor (EGF) and fibroblastic growth factor (FGF) in EVs suggests that EVs also have a direct role in oncogenesis. EVs are able to transfer proteins from malignant cells to neighbouring or to distant cells, which can promote cancer growth through potential effects on the microenvironment, inhibition of anticancer immune responses and the induction of angiogenesis. Interestingly, EVs have also been shown to facilitate metastasis by inducing epithelial-to-mesenchymal transition (EMT) and other changes in the target microenvironment [73] [74] [75] . 
Interstitial spaces
Small, narrow spaces between tissues that are typically filled with interstitial liquid. cellular antiviral factors that are carried by EVs could facilitate an antiviral response in neighbouring cells 99 . In addition, EVs that are packaged with viral proteins may function to introduce these proteins and activate B cells and T cells through the endosomal presentation of proteins, a process termed cross-priming, rather than endogenous synthesis and presentation by MHC molecules. Thus, these bystander immune cells would become activated without actual viral infection 100, 101 . It is known that infection with HIV alters the repertoire of mi RNAs in infected cells [102] [103] [104] and considering that mi RNAs can be packaged into EVs 13 , the EVs from cells infected with HIV may contain distinct mi RNAs compared with EVs from uninfected cells. In the context of AIDS-defining malignancies, such as Kaposi sarcoma, EVs isolated from patients who are infected with HIV have distinct mi RNAs profiles before and concurrent with lesion development 13, 105 . Initially, HIV was thought to encode mi RNAs 106 , but these observations have since been questioned 107, 108 . It is becoming clear that mi RNAs that have Drosha-dependent hairpinlooped precursors are not the only small RNAs that can be transcribed from the genomes of RNA viruses (including retroviruses) [109] [110] [111] and some of these RNA species have been found in EVs 112 . The potential roles that mi RNAs (as defined by their biogenesis and structural composition), or other small RNAs that do not fit the classical definition of mi RNAs, have in the function of EVs is an active area of investigation that is likely to reveal new properties that affect viral infection and pathogenesis 107, 108, 113 . EVs from cells that are infected with HIV contain the viral protein Nef [32] [33] [34] . In addition, soluble Tat protein circulates in interstitial spaces, blood and mucosal barriers, and can carry out biological activities, such as promoting angiogenesis and endothelial cell reprogramming 89, [114] [115] [116] . Soluble Tat has a fusogenic peptide sequence that enables its efficient uptake into cells 117, 118 . As the HIV Tat protein does not need to be incorporated into EVs to enter cells, the biological relevance of its incorporation into EVs remains unclear. Nef associates with membranes and with proteins of the vesicular trafficking system, such as ALIX and others 119, 120 . Nef can be incorporated into EVs and may modulate the contents of EVs, including mi RNAs [32] [33] [34] 121 ; however, some researchers have contested these findings, as the level of Nef in EVs is at the limit of detection 122 . In summary, HIV provides an example of how latent viruses may use EVs to maintain a susceptible host environment over long periods of time, during which virus replication is minimal.
EBV. EBV, which is a gammaherpesvirus, is a major human pathogen and was the first human tumour virus to be identified 3 . EVs that contain viral proteins were first shown to be produced from B cells that were infected with EBV. The major EBV oncoprotein, LMP1, was identified in EVs secreted from cell lines that were infected with EBV 123 . LMP1 is required for B lymphocyte transformation (reviewed in REF. 124 ). The incorporation of this protein into EVs has not only been demonstrated in B cells and epithelial cells cultured in vitro but has also been detected in exosomes in the serum of patients with EBV-associated tumours and in serum from mice that have nasopharyngeal carcinomas (NPCs) 16, 125 . The interaction between LMP1 and the tetraspanin CD63 may contribute to the selective incorporation of LMP1 into EVs 48, 126 , similar to the selective palmitoylation of LMP1 (REF. 47 ). In addition, LMP1 is known to localize to lipid rafts and such rafts are present in the membranes of EVs 127 . It is possible that the presence of LMP1 in lipid rafts may contribute to the enrichment of LMP1 in MVBs and subsequent enrichment in EVs.
EVs secreted from B cells that contain LMP1 inhibit T cell proliferation and natural killer (NK) cell cyto toxicity 123, 128 . EVs that are secreted from NPC cells infected with EBV also contain galectin 9, which is thought to contribute to these immunosuppressive effects [128] [129] [130] . It has long been known that NPC tumours infected with EBV are infiltrated with T cells that are seemingly non-functional, as they do not kill tumour cells or impair tumour growth. This lack of activity may reflect the abundant secretion of EVs during infection with EBV, thus representing another viral immune evasion strategy.
Importantly, EVs that contain LMP1 have been shown to deliver activated signalling proteins into uninfected cells 131 . This potentially important feature of EVs was revealed in studies that showed that epidermal growth factor receptor (EGFR), which is highly induced by LMP1, was also abundant in EVs that contained LMP1 (REF. 16 ). LMP1 has also been shown to increase the level of phosphoinositide 3-kinase (PI3CA) in lipid rafts and EVs. The delivery of LMP1, EGFR and PI3CA through EVs induced growth-stimulating signalling pathways in recipient cells, including the activation of the phosphoinositide 3-kinase (PI3K) target, serine/threonine kinase AKT1, and extracellular signalrelated kinase 1 (ERK1; also known as MAPK3) 131 . An early study revealed the increased incorporation of fibroblast growth factor 2 (FGF2) from cells that expressed LMP1 into EVs, which could potentially affect the tumour environment through the direct stimulation of the growth of infected cells or supporting stromal cells 132 . In addition, it was demonstrated that LMP1 activates hypoxia-inducible factor 1α (HIF1α), which is also transferred by EVs into recipient cells and can activate various targets 133 . HIF1α is the major transcriptional regulator under hypoxic conditions, which are characteristic of many tumours, and could promote the survival of tumour cells in an anoxic environment. An important target of HIF1α is vascular endothelial growth factor 1 (VEGF1), which induces angiogenesis. Thus, through the transfer of EVs, EBV can affect the growth of neighbouring cells.
It is also known that in tumours that are caused by infection with EBV, not all cells express LMP1. Therefore, the secretion and uptake of LMP1 into cells that do not express it, could affect the growth of additional tumour cells. This may be particularly important in the pathogenesis of NPC, in which not all cells express detectable levels of LMP1.
Principal component analysis
A statistical method used to uncover relationships defined by 10-1,000 or more correlated variables, which identifies the factors that contribute to variability. Typically, the first 3-5 principal components are composed of the variables that have the greatest explanatory power.
Spectral counting
A method that determines the relative presence or absence of a peptide in a pair of samples analysed by mass spectroscopy.
Primary effusion lymphoma
A diffuse large B cell lymphoma that is caused by Kaposi sarcoma-associated herpesvirus.
Paracrine
Affecting the physiology of neighbouring cells without cell-to-cell contact, typically through cytokines or growth factors. If the growth factors act on the same cell type from which they originate the process is called an autocrine loop.
LMP1 may also modulate the selective sorting of proteins into the exosomal pathway, which suggests that EBV manipulates these pathways for intercellular communication. The possibility of LMP1-mediated specific effects on the content of EVs was revealed from quantitative proteomics and 2D gel analysis of EVs purified from B cell lines that were uninfected, or infected with EBV, KSHV or both viruses 131 . Analysis of LMP1-positive versus LMP1-negative cell lines revealed 217 protein spots with significantly different expression (P < 0.05). Principal component analysis to identify the distinguishing features among the EVs from these different cells lines revealed that LMP1 was a major determinant of the variance between samples. This strongly suggested that LMP1 had an effect on the exosomal protein content and provided additional evidence for specific viral effects on this process.
Spectral counting analysis also indicated that both KSHV and EBV had distinct effects on the contents of EVs and that these effects reflected cellular changes that occur in infected cells 131 . Gene ontology pathway analyses of proteins that were identified in EVs derived from infected cells predicted that EVs from cells infected with EBV and KSHV modulate cell death and survival, ribosome function and protein synthesis. Analyses of the contents of EVs from infected cells also indicated that EVs from cells infected with KSHV could affect cellular metabolism and that EVs from cells infected with EBV could activate cellular signalling mediated by integrins, actin, IFN and nuclear factor-κB (NF-κB), through the transfer of crucial regulatory proteins in these pathways.
A novel finding was that EBV-encoded mi RNAs were also detected in EVs that were secreted from cells infected with EBV and that these viral mi RNAs could then be transferred to uninfected recipient cells 16, 24 ( FIG. 2d) . The viral mi RNAs were shown to specifically decrease previously identified viral miRNA targets, thus providing evidence of the functional delivery of mi RNAs through EVs 24 . This transfer also probably occurs in vivo, as uninfected B cells that were isolated from patients with NPC contained viral mi RNAs. Interestingly, EVs from NPCs have distinct patterns of EBV miRNA abundance compared with the intracellular levels in the producing cells 16 . This observation supports the hypothesis that there is selective sorting of specific mi RNAs into EVs.
In addition to viral proteins and mi RNAs, 5′pppE-BER1, which is a small non-coding viral RNA, has also been found in EVs secreted from cells infected with EBV 134 . EBER1 is the most abundant viral RNA in infected cells and 5′pppEBER1 enhances the immune function of dendritic cells. This unusual finding indicates that EVs may contribute to autoimmune diseases, such as systemic lupus erythematosus, that have been linked to infection with EBV 3 . Overall, these findings suggest that EBV modulates EVs to secrete viral and cellular proteins and mi RNAs that probably contribute to intercellular communication and affect the function of uninfected cells. Modulating the content of EVs could be important for affecting tumour environments by inducing cell growth, promoting angiogenesis and inhibiting immune cell function, and also for potentiating metastasis.
KSHV. KSHV causes Kaposi sarcoma and various hyperplastic and neoplastic B cell disorders, such as primary effusion lymphoma (PEL). PEL usually presents with liquid effusions without tumour masses in serous body cavities. Cell-free primary PEL fluid is highly enriched in tumour-derived EVs 13 . Primary KSHV infection is asymptomatic in a healthy host and results in lifelong latency. In rare cases, immune reconstitution inflammatory syndrome follows, which is associated with severe disease flares and clinical symptoms that are consistent with infection and inflammation. Common to all Kaposi sarcoma pathology is neo-angiogenesis and the infiltration of the environment that surrounds the tumour cells with uninfected non-transformed host cells, such as endothelial cells and macrophages. Aside from haemangioma, Kaposi sarcoma is the most angiogenic cancer, and therefore the study of KSHV can be useful for understanding the interactions between EVs and endothelial cells.
KSHV angiogenesis is driven by paracrine effectors, such as soluble cytokines and the growth factors VEGF1 and platelet-derived growth factor 1 (PDGF1), PDGF2, PDGF3 and PDGF4 (REF. 135 ). Initially, the paracrine drivers of Kaposi sarcoma were thought to be only soluble cytokines (for example, VEGF and PDGF or interleukin-6 (IL-6)). More recently, EVs have been shown to mediate some of these phenotypes (such as endothelial cell remodelling, migration and proliferation), independent of IL-6 (REF. 13 ), as PEL and Kaposi sarcoma tumour cells release large quantities of EVs, which drive endothelial cell proliferation and invasion in the presence of neutralizing antibodies to IL-6 (REF. 13 ).
KSHV encodes several viral mi RNAs 136, 137 , which constitute up to 50% of all mi RNAs in infected cells 138 . Viral mi RNAs and mRNAs have been detected in virion preparations of almost all herpesviruses 14, 15, 139 . Viral mi RNAs are also readily detected in EVs derived from Kaposi sarcoma tumours 140 . The levels of viral mi RNAs in EVs are 10-100 fold higher than those reported for virion-associated mi RNAs. Thus, owing to the similar biophysical characteristics of virions and EVs, it is unclear whether reports of virion-associated miRNAs reflect contamination by EVs.
Several lines of evidence have attributed phenotypes that were previously attributed to mi RNAs incorporated into virions to mi RNAs incorporated into EVs. These include the biochemical separation of EVs by positive selection on anti-CD63 beads (a marker of EVs; FIG. 3) , as well as genetic approaches, such as the detection of KSHV miRNA-containing EVs in KSHV-miRNA transgenic mice, which cannot produce the virus 13 . This suggests that during KSHV latency viral mi RNAs can be incorporated into EVs through the same host cellular pathways that load host mi RNAs into EVs. A large proportion of host mi RNAs are also incorporated into systemically circulating EVs 13 . Thus, the identity and abundance of mi RNAs in EVs represents a snapshot of their cellular origin. A more active model hypothesizes that viral mi RNAs and proteins are specifically and differentially loaded into EVs 16, 24, [42] [43] [44] [45] .
Infection with KSHV changes many aspects of the physiology of the infected cell, including lipid metabolism and presumably vesicle biogenesis. The protein composition of EVs and their secretion are modulated during viral reactivation from PEL cell lines 16 , although KSHV proteins have not been detected in EVs 131 . The replication and maturation of KSHV are much slower than with other viral infections 3 . In culture models of KSHV, the number of infectious virions is approximately 10 5 copies per ml, compared with 10 7 copies per ml for EBV or 10 9 copies per ml for flaviviruses 141 . In patients with Kaposi sarcoma, the viral titre ranges from 10 3 -10 5 copies per ml, whereas EBV or HCMV titres exceed 10 6 copies per ml in patients, and viral titres during hepatitis virus infections range from 10 5 -10 9 copies per ml. In the case of KSHV, we speculate that preventing the accumulation of highly immunogenic virions, and instead using host EVs to distribute viral mi RNAs to neighbouring cells, represents a novel strategy to persist in the host (FIG. 2e) . In this model, miRNAs in EVs provide an evolutionary advantage for virus spread by priming neighbouring cells for infection. KSHV infects and replicates primarily in endothelial cells; these need to be attracted and re-programmed to migrate towards the initially infected cell. PEL-derived EVs confer this property to uninfected endothelial cells in culture through the transfer of viral mi RNAs or protein-coding RNAs 142, 143 . In summary, KSHV represents another example by which a virus can modulate the host local environment through EV reprogramming. Interfering with the release of EVs during infection with KSHV may therefore have the potential to limit virus spread and/or pathology.
Alphaherpesviruses and betaherpesviruses. Alphaherpes viruses, such as HSV-1, and betaherpesviruses, such as HCMV, also influence the biogenesis pathways of EVs and use these pathways for egress [144] [145] [146] . Similar to the biogenesis of EVs, the maturation of HCMV virions is dependent on the ESCRT machinery and virions contain cellular markers that are associated with EVs 147, 148 . Some of the observed systemic and biological phenotypes that are associated with infection with HSV-1 and HCMV may be the result of massive re-programming of MHC I and MHC II trafficking from the secretory pathway. HCMV replicates in various cell types, including endothelial cells that line the blood and lymphatic vasculature, and can cause graft rejection in organ transplantation. EVs that are released from endothelial cells infected with HCMV can exacerbate allogeneic graft rejection 149 . More recently, it was shown that the immune sensor stimulator of IFN genes (STING) is incorporated into EVs that are secreted from cells infected with HSV-1 and that the STING ligand cyclic GMP-AMP synthase (cGAMP) is present in EVs that are released from cells infected with murine cytomegalovirus 150, 151 . The cGAMP nucleotide triggers the recognition of foreign molecules through STING and also augments RIG-I and TLR signalling, which leads to a marked interferon response. It is possible that introducing cGAMP into cells through EVs may trigger an antiviral response in neighbouring cells 152 . This represents perhaps the most direct demonstration that cellular EVs can have antiviral and pro-host roles.
The HSV-1 viral mi RNAs miR-H28 and miR-H29 are also incorporated into EVs. These have been shown to have pro-viral roles in infection and facilitate the infection of neighbouring cells 153 , perhaps by weakening innate immune defences. Further studies are required to fully understand this observation, but it seems counterintuitive for the same infected cell to secrete pro-viral and antiviral EVs at the same time. More likely, these distinct effects that were identified in cultured cell lines represent different steps in natural infection, perhaps by altering the initial infection of different cell types, enhancing or limiting systemic spread throughout the host, or by altering viral virulence to facilitate persistence or the establishment of latency. In summary, herpesviruses, by virtue of their large genomes (encoding >100 proteins, as well as mi RNAs and long non-coding RNAs (lncRNAs)) 154 , modulate the biogenesis and function of EVs through several independent mechanisms.
Summary and outlook
In this Review, we have discussed the multiple ways in which different viruses manipulate EVs for their benefit to increase their persistence, pathogenesis and transmission. In recent years, EVs have emerged as specific carriers of cellular and viral components, including mi RNAs, proteins and viral genomes. This can happen during active viral replication or during viral latency. The majority of experiments that have been carried out have explored how EVs can deliver cytoplasmic contents from one cell to other cells in the surrounding environment in the absence of cell-cell fusion. However, the role of EVs can also be more far-reaching than the local environment Nature Reviews | Microbiology most virions co-purify with EVs under these conditions. Next, EVs are immunopurified using antibodies that bind to proteins present on the surface of EVs. Virions, which do not contain these proteins, are left behind in the column flow-through. Virions can also be purified by using an antibody that binds to a virion protein (not shown). b | Electron micrograph of EVs that are derived from a tumour cell line. into which they are released (FIG. 4) ; the presence of EVs in the blood and the lymphatic system suggests that EVs are able to transport cargo over long distances.
The role of EVs in the pathogenesis of viruses is similar to their role in cancer metastasis, in which they are known to prime distant sites (soil) for the reception of meta static cells (seed)
. EVs and their effects on recipient cells are mediated by individual EVs, and the recipient cells do not produce or amplify these EVs. This is in contrast to cells infected by viruses, which can produce thousands of progeny from a single infected cell (FIG. 4) . However, during chronic or latent viral infection, a single infected cell may actually release many more EVs than infectious virus particles; therefore, the use of EVs to prime and enhance systemic viral infection is likely.
Experimental data that support a role for EVs in priming the innate immune response have been reported. Cargo in EVs can elicit a TLR-dependent immune response in mice that have tumours 155 or prime neighbouring cells, including DCs, to respond to viral infection by priming the adaptive immune response or through the release of interferon 134, 156 . During this scenario, EVs may have evolved a role for protection from pathogens, perhaps through the activation of innate immune responses in neighbouring cells. A role for EVs in adaptive immunity has already been established, in which EVs (or some specialized membrane-encapsulated vesicles) can efficiently cross-prime innate immunity and adaptive immune memory responses 27, 28, 30, 101, 157 . Importantly, it is likely that basic research in the biogenesis and fusion of EVs will be enhanced by previous, similar studies that characterized virion egress and entry. Many stages in the biogenesis of EVs are also used by viruses; for example, the ESCRT family of proteins during virus assembly and egress. Further study of viral effects on the pathways that involve EVs is likely to identify the crucial regulators of endosomal and exosomal trafficking in host cell physiology, as well as uncover new mechanisms that modulate host cells to determine the outcome of virus infections. Further study of the biology of EVs will provide a rich area to enhance our understanding of the complexities of viral redirection of cellular processes and the determination of how viral effects on the production and content of EVs contribute to both pathogenesis and persistence. 
